Axis Securities Report Highlights Positive Trends for Q2 FY25 The Indian pharmaceutical industry is poised for a robust year, with revenue growth projected at 8.5% year-on-year (YoY) for the second quarter of FY25, driven primarily by domestic formulations and strategic niche launches in the US market.
Cipla Ltd. made headlines on Tuesday with a significant update regarding its board of directors. Mustafa Khwaja Hamied, commonly known as MK Hamied, will step down from his role as vice-chairman and non-executive director. The resignation will be effective at the close of business on
To commemorate National Organ Donation Day, Bai Jerbai Wadia Hospital for Children honored the families of four young children who chose to donate organs following the heartbreaking declaration of brain death as well as its dedicated staff members. The selfless act provided a vital gift
RNA extraction free kit to deliver results in just 45 Min. Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd. With this, Cipla
Experts discuss Regulatory Reforms, Ease of Doing Business during Health & Wellness Week at India Pavilion The India Pavilion at EXPO2020 Dubai yesterday hosted a roundtable, ‘India –Pharmacy of the world’ as part of the ongoing Health & Wellness week, wherein several government and industry experts
As we observe World COPD Day, here are some of the important and alarming facts about COPD (Chronic Obstructive Pulmonary Disease). India is the ‘COPD Capital of the World’; our country has the highest number of COPD cases in the world COPD prevalence among the
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been selected in the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021. The DJSI family of indices is operated by one of the
On Monday, the companies said in a joint statement that India's Cipla (CIPL.NS) has signed a deal with Eli Lilly (LLY.N) to sell and distribute two of the U.S. drugmaker's best-selling diabetes treatments in the country. The companies said, Lilly will transfer its rights in India to sell, promote
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk* of severe COVID-19 Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced
Strengthens offerings & continues to be at the forefront of COVID care Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems
